Diagnosis and treatment of human dormancy syndrome

• US 7,288,257 B2
• Filed: 05/23/2003
• Issued: 10/30/2007
• Est. Priority Date: 05/23/2002
• Status: Expired due to Fees

• Current Assignee: Michael Powell
• Original Assignee: Michael Powell
• Inventors: Powell, Michael
• Primary Examiner(s): Davis; Ruth A
• Application Number:
  US10/444,845
• Publication Number:
  US 20030228628A1
• Time in Patent Office: 1,621 Days
• Field of Search: 424/198.1, 435/4, 530/380, 530/399
• US Class Current: 424/198.1
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: G01N 33/6896 Neurological disorders, e.g. Alzheimer's disease
• CPC Class Codes: G01N 33/78 Thyroid gland hormones , e.g. T3, T4, TBH, TBG or their receptors
• CPC Class Codes: Y02A 50/30 Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

New methods for diagnosis of human dormancy syndrome are provided. Human dormancy syndrome is characterized by elevated serum ratio of rT3/fT3 compared to a population of normal subjects from which subjects suffering from fibromyalgia, chronic fatigue, obesity, dementias including Alzheimer'"'"'s Disease and related dormancy conditions are excluded, and the presence of one or more findings related to reduced activity including torpor, chronic fatigue, insulin resistance, dementias, obesity and the like. Treatment of human dormancy syndrome is directed toward increasing fT3 levels or decreasing rT3 levels, or both, using pharmaceutical and/or behavioral methods. Other conditions that are associated with HDS can also be treated using T3 therapy, with or without specific psychological, behavioral or pharmaceutical therapies.

Claims

1. A method for treating a patient, comprising:

(a) measuring serum levels of rT3 and fT3 of said patient;

(b) calculating the ratio of rT3/fT3, wherein said ratio is above about 4; and

(c) determining the presence of one or more findings selected from the group consisting of fibromyalgia, increased pain perception, elevated substance P in the cerebrospinal fluid, chronic back pain, fatigue, sympathetic dystrophy, insulin resistance, depression, centripetal obesity, exercise intolerance, and cognitive impairment, wherein the findings are associated with human dormancy syndrome; and

(d) administering T3 to decrease the ratio of serum rT3/fT3 to below about 4 and said finding returns substantially to normal.

2. The method of claim 1, further comprising at least one therapy selected from the group consisting of physical therapy and occupational therapy.

3. The method of claim 1, further comprising at least one therapy selected from the group consisting of psychotherapy, cognitive behavioral therapy, exposure therapy, beta-adrenergic antagonist therapy, serotonin reuptake inhibitor therapy, MgSO₄ therapy, magnesium therapy, oxytocin therapy, dopamine increasing therapy, glucocorticoid therapy, ACTH therapy, and nitric oxide enhancing therapy.

4. The method of claim 1, further comprising nitric oxide enhancing therapy.

5. The method of claim 1, further comprising administering a pharmaceutical agent selected from the group consisting of melatonin, testosterone, oxytocin, selenium, iodine, magnesium and nitroglycerine.

6. The method of claim 1, wherein said finding is fibromyalgia.